Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program.
Merrill Pauline T, Clark W Lloyd, Banker Alay S, Fardeau Christine, Franco Pablo, LeHoang Phuc et al.
Intravitreal sirolimus (440 μg) effectively reduced inflammation in noninfectious posterior uveitis with good safety and minimal IOP impact, offering a new treatment option.